Abstracts tagged "Disease Activity"

Abstract Number: 599 • 2014 ACR/ARHP Annual Meeting
Is There Any Gender Specific Difference in the Cut Off Values of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Axial Spondyloarthritis?
Erkan Kilic¹, Gamze Kilic¹ and Salih Ozgocmen², ¹Division of Rheumatology, Dept. PRM, Erciyes University, Faculty of Medicine, Kayseri, Turkey, ²Division of Rheumatology, Dept.PRM, Erciyes University, Faculty of Medicine, Kayseri, Turkey
Background/Purpose Axial spondyloarthritis (ax-SpA) consisted patients with advanced axial SpA or ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA). Evaluation of disease activity in axSpA…
Abstract Number: 367 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying…
Abstract Number: 2926 • 2014 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy
Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Sonia Cabrera-Villalba¹, Julio Ramirez¹, Andrea Cuervo¹, Virginia Ruiz-Esquide¹, Azucena González Navarro², Jordi Yagüe³, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Calprotectin is a major S100 leucocyte protein, is associated to disease activity in rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients. Calprotectin is a potentially…
Abstract Number: 2585 • 2014 ACR/ARHP Annual Meeting
Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis
Grigorios Sakellariou¹, Spyros Gerou², Dimitrios Oikonomou³ and Fares Sayegh⁴, ¹Rheumatology, 424 General Military Hospital, Thessaloniki, Greece, ²Laboratories "Analysis", Thessaloniki, Greece, ³Biopathology, 424 General Military Hospital, Thessaloniki, Greece, ⁴3rd Orthopaedic, "Papageorgiou" General Hospital, Thessaloniki, Greece
Background/Purpose: In patients with ankylosing spondylitis (AS), smoking is associated with increased disease activity and more radiographic damage. However, the mechanisms underlying the effects of…
Abstract Number: 2391 • 2014 ACR/ARHP Annual Meeting
Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice
G. Avila¹, Arnald Alonso¹, María América López-Lasanta¹, Andrea Pluma-Sanjurjo², C. Diaz² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose Biological therapies (BTs) have greatly improved the outcomes in RA patients and nowadays clinical remission (REM) and low disease activity (LDA) have become realistic…
Abstract Number: 1809 • 2014 ACR/ARHP Annual Meeting
Is Team Care Better? a Comparison of Rheumatoid Arthritis Disease Activity Among Patients Cared for in Practices with Nurse Practitioners and Physicians Assistants Versus Rheumatologist Only
DH Solomon^1,2, Liana Fraenkel³, Bing Lu¹, Erika Brown¹, Peter Hsun Tsao⁴, Elena Losina⁵, Jeffrey N. Katz⁶ and Asaf Bitton⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁷Medicine, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The Affordable Care Act proposes more widespread use of mid-level providers (MLPs), such as nurse practitioners and physician assistants, but little is known about…
Abstract Number: 1353 • 2014 ACR/ARHP Annual Meeting
Integrating Collection of Rheumatoid Arthritis Disease Activity and Physical Function Scores into an Academic Rheumatology Practice to Improve Quality of Care
Vladimir Chernitskiy¹, Andre DeVito², Naama Neeman², Niraj Sehgal², Jinoos Yazdany³ and Andrew J. Gross³, ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: The default design of our institutions’ electronic health record (EHR)(Epic Systems) was not optimally structured to systematically collect quality metrics for rheumatic disease management…
Abstract Number: 886 • 2014 ACR/ARHP Annual Meeting
Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status?
Nancy A. Baker¹, Heather Eng², Juan (June) Feng², Jason Lyons², Yong Gil Hwang³, Kimberly P. Liang⁴ and Larry W. Moreland⁵, ¹Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Disease remission is the goal of treat-to-target initiatives in rheumatoid arthritis (RA). There are multiple indices to measure disease activity and remission status including…
Abstract Number: 575 • 2014 ACR/ARHP Annual Meeting
Disease Activity Strongly Influences Work Productivity and Physical Health Related Quality of Life in Early Axial Spondyloarthritis: Data from the SPACE-Cohort
A Roeterink¹, M de Hooge², R. van den Berg², H Dagfinrud³, R Landewé⁴, M. van Oosterhout⁵, R Ramonda⁶, D. van der Heijde¹ and F van Gaalen², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Groene Hartziekenhuis, Gouda, Netherlands, ⁶Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: In early onset axial spondyloarthritis (axSpA), not much is known about the relationship between disease activity and work productivity loss (WPL) or disease activity…
Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting
Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Denis Choquette¹, Dalton Sholter², Isabelle Fortin³, Michael Starr⁴, Carter Thorne⁵, Milton Baker⁶, Regan Arendse⁷, Philip Baer⁸, Michel Zummer⁹, Jude Rodrigues¹⁰, Maqbool Sheriff¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Allen J Lehman¹⁴, Susan Otawa¹⁴ and May Shawi¹³, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Victoria, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Scarborough, ON, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Clinical Research and Arthritis Centre, Windsor, ON, Canada, ¹¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Inger Jorid Berg¹, Anne Grete Semb², Désirée van der Heijde^3,4, Tore K. Kvien⁴, Hanne Dagfinrud⁴, Jonny Hisdal^5,6 and Sella A. Provan², ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…
Abstract Number: 2392 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibodies (anti-CarPA) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Marije K Verheul², Anne Barton^3,4, Tarnya Marshall⁵, Bo Fu⁶, René E.M. Toes⁷, Deborah PM Symmons^1,4, Leendert A. Trouw⁷ and Suzanne MM Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁶Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-CarPA have been shown to predict development of rheumatoid arthritis (RA) in patients with arthralgia. However, little is known about their association with disease…
Abstract Number: 1631 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Richard Furie¹, Jill P. Buyon², R. Ramsey-Goldman³, Chaim Putterman⁴, Kenneth Kalunian⁵, Tyler O'Malley⁶, John Conklin⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: To assess the association between cell bound complement activation products (CBCAPS) and measures of disease activity and quality of life in systemic lupus erythematosus…
Abstract Number: 1352 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Disease Activity Assessment and Population Management Processes Used By Clinician Rheumatologists
Anne Winkler¹, James Mossell², Edmund MacLaughlin³, Drew Johnson⁴ and J. Timothy Harrington⁵, ¹Rheumatology, Winkler Medical Practice LLC, Springfield, MO, ²Arthritis & Osteo Center of South GA, Tifton, GA, ³Edmund L. MacLaughlin LLC, Cambridge, MD, ⁴Crescendo Bioscience, Inc., South San Francisco, CA, ⁵Joiner Associates LLC, Madison, WI
Background/Purpose: Timely disease activity assessment (DAA) and population management (PM) are known to reduce the burdens of chronic diseases, including RA. Currently, the measures and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].